Markets:

Overview

News

Currencies

International

Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

13.99 -0.14 (-0.99%)

Streaming Delayed Price Updated: 10:01 AM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022 ↗

June 01, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate ↗

May 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint ↗

May 18, 2022

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial...

Via Benzinga

Where Enanta Pharmaceuticals Stands With Analysts ↗

February 09, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

May 18, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

10 Biggest Price Target Changes For Tuesday ↗

May 10, 2022

Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading.

Via Benzinga

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

May 09, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022

May 02, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

March 29, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)

February 17, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial ↗

February 16, 2022

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has dosed the first subject in its Phase 1 trial of EDP-235, a coronavirus 3CL protease inhibitor, specifically designed as a...

Via Benzinga

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

February 16, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes ↗

February 11, 2022

Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.

Via Investor's Business Daily

Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference

February 10, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals: Q1 Earnings Insights ↗

February 08, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q1 earnings results on Tuesday, February 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

February 08, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021

February 01, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

What 10 Analyst Ratings Have To Say About Enanta Pharmaceuticals ↗

January 13, 2022

Analysts have provided the following ratings for Enanta Pharmaceuticals (NASDAQ:

Via Benzinga

Earnings Scheduled For February 8, 2022 ↗

February 08, 2022

Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

January 13, 2022

RBC Capital boosted KB Home (NYSE: KBH) price target from $46 to $55. KB Home shares rose 6.7% to $45.20 in pre-market trading. Cowen & Co. reduced the price target on...

Via Benzinga

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference

January 06, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 04, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

7 A-Rated Biotechs to Buy for the Long Run ↗

December 03, 2021

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

Via InvestorPlace

Where Enanta Pharmaceuticals Stands With Analysts ↗

November 24, 2021

Over the past 3 months, 11 analysts have published their opinion on Enanta Pharmaceuticals (NASDAQ:

Via Benzinga

56 Biggest Movers From Yesterday ↗

November 24, 2021

Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating...

Via Benzinga

Enanta Pharmaceuticals, inc (ENTA) Q4 2021 Earnings Call Transcript ↗

November 22, 2021

ENTA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

November 22, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

52 Biggest Movers From Friday ↗

November 22, 2021

Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland Technologies highlighted the launch of second...

Via Benzinga

Earnings Scheduled For November 22, 2021 ↗

November 22, 2021

Companies Reporting Before The Bell • Cerence (NASDAQ:CRNC) is estimated to report quarterly earnings at $0.56 per share on revenue of $97.92 million. • Avaya...

Via Benzinga

The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

All News about Enanta Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today